Efficacy and safety of once-weekly semaglutide vs sitagliptin as add-on to metformin and/or thiazolidinediones after 56 weeks in subjects with type 2 diabetes (SUSTAIN 2)

被引：0
|
作者：
Ahren, B. [1 ]
Comas, L. Masmiquel [2 ]
Kumar, H. [3 ]
Sargin, M. [4 ]
Karsbol, J. Derving [5 ]
Jacobsen, S. Hald [5 ]
Chow, F. [6 ]
机构：
[1] Lund Univ, Lund, Sweden
[2] Hosp Quiron Palmaplanas, Palma De Mallorca, Spain
[3] Amrita Inst Med Sci & Res Ctr, Kochi, India
[4] Kartal Lufti Kirdar Training & Res Hosp, Istanbul, Turkey
[5] Novo Nordisk AS, Soborg, Denmark
[6] Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China
来源：
DIABETOLOGIA | 2016年 / 59卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
767
引用
收藏
页码：S365 / S365
页数：1
相关论文
共 50 条
  • [41] Improved treatment satisfaction in patients with type 2 diabetes treated with once-weekly semaglutide in the SUSTAIN trials
    Jendle, Johan
    Birkenfeld, Andreas L.
    Polonsky, William H.
    Silver, Robert
    Uusinarkaus, Kari
    Hansen, Thomas
    Hakan-Bloch, Jonas
    Tadayon, Sayeh
    Davies, Melanie J.
    DIABETES OBESITY & METABOLISM, 2019, 21 (10): : 2315 - 2326
  • [42] Efficacy and safety of once-weekly semaglutide in Japanese individuals with type 2 diabetes in the SUSTAIN 1, 2, 5 and 9 trials: Post-hoc analysis
    Araki, Eiichi
    Harashima, Shinichi
    Nishida, Tomoyuki
    Nakamura, Jiro
    JOURNAL OF DIABETES INVESTIGATION, 2022, : 1971 - 1980
  • [43] The effects of once-weekly semaglutide on beta-cell function in subjects with type 2 diabetes
    Kapitza, Christoph
    Dahl, Kirsten
    Jacobsen, Jacob Bonde
    Axelsen, Mads Buhl
    Bergan, Eirik Quamme
    Flint, Anne
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S127 - S128
  • [44] Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
    Pierre Johansen
    Jonas Håkan-Bloch
    Aiden R. Liu
    Peter G. Bech
    Sofie Persson
    Lawrence A. Leiter
    PharmacoEconomics - Open, 2019, 3 : 537 - 550
  • [45] Efficacy and Safety of Supaglutide as Add-on to Metformin in Patients with Type 2 Diabetes
    Anwar, Dilbar
    Bao, Yuqian
    Zhou, Yue
    Chen, Si
    Zhou, Jian
    Li, Liang
    Cheng, Zhifeng
    Dong, Xiaolin
    Shi, Xiaoxia
    Su, Xiuhai
    Li, Liping
    Wang, Haifang
    Wang, Yihua
    Li, Shu
    Li, Qingju
    Li, Xing
    Liu, Ming
    Sun, Jiao
    Zhao, Naiqing
    Yang, Yehong
    Ma, Jianhua
    Li, Yiming
    Wang, Qinghua
    Jia, Weiping
    DIABETES, 2023, 72
  • [46] Efficacy and safety of supaglutide as add-on to metformin in patients with type 2 diabetes
    Anwar, D.
    Bao, Y.
    Zhou, Y.
    Chen, S.
    Zhou, J.
    Li, L.
    Cheng, Z.
    Dong, X.
    Shi, X.
    Zhao, N.
    Yang, Y.
    Ma, J.
    Li, Y.
    Wang, Q.
    Jia, W.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S322 - S322
  • [47] Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
    Johansen, Pierre
    Hakan-Bloch, Jonas
    Liu, Aiden R.
    Bech, Peter G.
    Persson, Sofie
    Leiter, Lawrence A.
    PHARMACOECONOMICS-OPEN, 2019, 3 (04) : 537 - 550
  • [48] EFFICACY AND SAFETY OF ANAGLIPTIN COMPARED WITH SITAGLIPTIN AS AN ADD-ON FOR PATIENTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED WITH METFORMIN MONOTHERAPY
    Jin, S. -M.
    Park, S. W.
    Yoon, K. -H.
    Lee, M. -K.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 106 : S135 - S136
  • [49] Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial
    Zinman, Bernard
    Bhosekar, Vaishali
    Busch, Robert
    Holst, Ingrid
    Ludvik, Bernhard
    Thielke, Desiree
    Thrasher, James
    Woo, Vincent
    Philis-Tsimikas, Athena
    LANCET DIABETES & ENDOCRINOLOGY, 2019, 7 (05): : 356 - 367
  • [50] Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial
    Lingvay, Ildiko
    Benamar, Malik
    Chen, Liming
    Fu, Ariel
    Jodar, Esteban
    Nishida, Tomoyuki
    Riveline, Jean-Pierre
    Yabe, Daisuke
    Zueger, Thomas
    Rea, Rosangela
    DIABETOLOGIA, 2025, : 739 - 751
12345